Skip to main content
Premium Trial:

Request an Annual Quote

MDS Pharma, Compendia to Develop Cancer PGx Platform

NEW YORK (GenomeWeb News) – MDS Pharma Services and Compendia Bioscience have collaborated to develop a pharmacogenomic platform for use in cancer patients and therapeutics research, MDS said today.

The new OncoPredictor combines MDS Pharma Services' OncoPanel, which offers high-content screening of up to 240 cancer cell lines for sensitivity to specific cancer drugs and drug combinations, with Compendia's Oncomine database. The Compendia database of cancer genomic profiles and its analysis application provides genomic characterization and comparison of cancer cell lines to 2,000 disease signatures from 27,000 reference patients.

The combined OncoPredictor system will analyze drug sensitivity and resistance of novel drugs and drug combinations for cancer research.

"Our pharmaceutical and biotechnology clients seek to determine the efficacy of their compounds across cancer genotypes and patient phenotypes," Compendia's CEO Dan Rhodes said in a statement. "OncoPredictor will help provide the answer with technology for information-based lead selection, predictive in vivo study design and biomarker development."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.